### Impact of COVID-19 on Diabetes Research In early 2020, diabetes research was thriving with numerous clinical trials and promising projects. However, the COVID-19 pandemic brought many of these efforts to a halt. Researchers like Dr. John Burd, who were conducting clinical trials on supplements like Lysulin, found their labs empty and their projects paused. Funding, already scarce, became even harder to secure as fundraising events were canceled and donations dwindled. Organizations like TrialNet, which focuses on preventing type 1 diabetes, also faced significant setbacks. Dr. Carla Greenbaum expressed concerns about losing momentum and time, with several trials coming to a standstill. The pandemic disrupted lab access, and national shelter-in-place orders kept trial participants at home, further stalling research. Despite these challenges, some organizations found ways to adapt. The Diabetes Research Institute in Florida, for example, managed to secure funding and continue their work. The Helmsley Charitable Trust allocated emergency grants to address pandemic-related issues while maintaining their research priorities. Innovative solutions emerged to support researchers. Monica Westley launched The Sugar Science (TSS), a digital platform for diabetes researchers to collaborate and share ideas. This initiative provided a much-needed space for scientists to connect and continue their work remotely. While the pandemic has undoubtedly caused delays and increased costs, it has also accelerated the adoption of virtual methods for conducting research. For instance, Joslin Diabetes Center transitioned many of their studies to virtual formats, allowing them to continue despite the shutdown. In summary, the COVID-19 pandemic has posed significant challenges to diabetes research, but it has also spurred innovation and adaptation. Researchers are finding new ways to collaborate and continue their work, ensuring that progress in diabetes research does not come to a complete halt.